FDA
24th July 2019

FDA Psychopharmacologic Drugs Advisory Committee (PDAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM) Endorse Esketamine

On February 12th, 2019, Janssen Pharmaceuticals, Inc. discussed their New Drug Application (NDA) #211243.

FDA Psychopharmacologic Drugs Advisory Committee (PDAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM) Endorse Esketamine

On February 12th, 2019, Janssen Pharmaceuticals, Inc. discussed their New Drug Application (NDA) #211243 for Esketamine nasal spray during a joint meeting of the FDA’s DSaRM and PDAC. The proposed indication is for the maintenance of treatment-resistant depression (TRD).

The sponsor explained that TRD occurs when patients diagnosed with major depressive disorder (MDD) are unresponsive to at least two antidepressants. TRD is an extremely serious, life-threatening condition with increased rates of suicide, hospitalization, and impairment in daily functioning. According to the National Institute of Mental Health (NIHM), 16.2 million adults in the US have at least one MDD episode.

Esketamine works at the N-Methyl-D-aspartic acid (NMDA) neuroreceptors as an antagonist. It also enables activation of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor. This increases signaling of neurotrophic factors that support both a rapid onset and long-term antidepressant effects. This mechanism can help stabilize and improve TRD-related symptoms. Esketamine’s efficacy and safety was substantiated by an extensive clinical development program consisting of 19 Phase I, 4 Phase II and 5 Phase III clinical studies.

The committees answered 2 discussion questions and 3 voting questions. The most important voting question was whether the benefits of therapy outweigh the risks and if the committees supported approval of the drug. This resulted in a resounding confirmation (14 YES to 2 NO and 1 ABSTAIN).

The committee members in support explained that esketamine demonstrated sufficient evidence of effectiveness through well-characterized outcomes. They also supported the FDA’s proposed Risk Evaluation and Mitigation Strategy (REMS). Those who voted “NO” expressed their concerns regarding esketamine-related deaths, believing that the evidence supporting its efficacy was inadequate. They also raised concern about the safety of REMS.

The agency is not obligated to follow its panels’ recommendation, but normally does so.

On March 6th, FDA approved the Spravato (Esketamine) nasal spray for TRD.

ISS has almost two decades of experience in developing regulatory strategies including support for FDA Advisory Committee meetings. We are involved in more FDA AdComms per year than even the largest pharmaceutical companies. For more information on how ISS can help you prepare for your next meeting, contact info@innovativescience.net

This post was authored by Sharon Christian. Sharon is a summer intern at ISS and an undergraduate student at Rutgers University.

DO YOU HAVE AN UPCOMING ADVISORY COMMITTEE MEETING?

Download ISS' Essential Guide to Preparing for a Meeting at the FDA White Oak Campus.

  • This field is for validation purposes and should be left unchanged.

Recent Related Articles

Best Tips for Medical Device Manufacturers to Write a Compelling Substantial Equivalence Section for their FDA 510k Submission
01 July 2020
Best Tips for Medical Device Manufacturers to Write a Compelling Substantial Equivalence Section for their FDA 510k Submission

Over the past few years, the number of ex-US manufacturers submitting a Class II exempt 510k device registration has increased substantially. For companies with medical devices that are approved and successful in a foreign market, the logical next step is to introduce their product into the US, which has one of the most lucrative healthcare markets in the world. Read more

Evolving FDA Thinking on Advisory Committee Meetings Related to Foods, Drugs, and Devices
25 June 2020
Evolving FDA Thinking on Advisory Committee Meetings Related to Foods, Drugs, and Devices

FDA advisory committee meetings are important regulatory events for many manufacturers on the path to marketing approval. These meetings can quite literally result in the approval or rejection of a product based on the panel’s vote. Read more

NDA vs. OTC Monograph: Which Pathway is Right for You?
22 June 2020
NDA vs. OTC Monograph: Which Pathway is Right for You?

One of the main challenges our clients face is determining which regulatory pathway is best for their products. For example, what if an OTC product has a Monograph active ingredient but that ingredient is present at a different amount than the permitted amount? Or what if the label claims a novel indication not specified in a Monograph? If you are debating pursuit of either regulatory pathway for your OTC drug, it is critical to consider cost, timeline, and label claims to ensure your products has a unique stance in today’s market. Read more

4 Problems Importing Rapid Antibody Tests for Coronavirus
19 June 2020
4 Problems Importing Rapid Antibody Tests for Coronavirus

US distributors and agents trying to import rapid antibody tests for coronavirus face a number of obstacles. The good news is that FDA has opened up the Emergency Use Authorization (EUA) program to include SARS-CoV-2 (the virus) and COVID-19 (the disease), expediting time to market. Read more

Let’s work together

The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us today

Contact us